1. 1596 Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia (CIN/FN) prophylaxis with biosimilar filgrastim and development of an outcomes risk calculator (MONITOR-GCSF study). (September 2015) Authors: Aapro, M.; Ludwig, H.; Bokemeyer, C.; Gascón, P.; Boccadoro, M.; Turner, M.; Denhaerynck, K.; MacDonald, K.; Abraham, I. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S236 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 616 Fanconi anemia, complementation group A (FancA) overexpression confers radioresistance to oral keratinocytes. (September 2015) Authors: Gimenez-Aznar, I.; Michna, A.; Ludwig, H.; Braselmann, H.; Klein, D.; Ohrt, M.; Schötz, U.; Kuger, S.; Schneider, L.; Schüttrumpf, L.; Jendrossek, V.; Belka, C.; Zangen, V.; Unger, K.; Zitzelsberger, H.; Lauber, K.; Heß, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Fast-Painting of Human Metaphase Spreads Using a Chromosome-Specific, Repeat-Depleted DNA Library Probe. (May 1998) Authors: Durm, M.; Schüssler, L.; Münch, H.; Craig, J.; Ludwig, H.; Hausmann, M.; Cremer, C. Journal: Biotechniques Issue: Volume 24:Number 5(1998) Page Start: 820 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P864: CTPS1 IS A NOVEL THERAPEUTIC TARGET IN MYELOMA - SELECTIVE SMALL MOLECULE INHIBITION DELIVERS SINGLE AGENT ACTIVITY AND SYNERGISES WITH ATR INHIBITION. (23rd June 2022) Authors: Pfeiffer, C.; Beer, P.; Asnagli, H.; Bolomsky, A.; Grandits, A.; Schneller, A.; Huber, J.; Zojer, N.; Schreder, M.; Parker, A.; Ludwig, H. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 757 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P873: CARFILZOMIB RESISTANCE IS ASSOCIATED WITH SIGNIFICANT DEREGULATION OF THE BH3 FAMILY PROTEINS. (23rd June 2022) Authors: Schneller, A.; Bolomsky, A.; Zojer, N.; Schreder, M.; Ludwig, H. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 766 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. (8th April 2019) Authors: Bringhen, S.; Milan, A.; D'Agostino, M.; Ferri, C.; Wäsch, R.; Gay, F.; Larocca, A.; Offidani, M.; Zweegman, S.; Terpos, E.; Goldschmidt, H.; Cavo, M.; Ludwig, H.; Driessen, C.; Auner, H. W.; Caers, J.; Gramatzki, M.; Dimopoulos, M. A.; Boccadoro, M.; Einsele, H. Journal: Journal of internal medicine Issue: Volume 286:Number 1(2019) Page Start: 63 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. S179: RANDOMIZED COMPARISON BETWEEN KRD AND KTD INDUCTION, FOLLOWED BY K MAINTENANCE OR OBSERVATION IN TRANSPLANT NON-ELIGIBLE PATIENTS WITH NDMM (AGMT-MM02 TRIAL). (23rd June 2022) Authors: Ludwig, H.; Melchardt, T.; Sormann, S.; Zojer, N.; Andel, J.; Hartmann, B.; Tinchon, C.; Gunsilius, E.; Podar, K.; Egle, A.; Willenbacher, W.; Wöll, E.; Schreder, M.; Ruckser, R.; Bozic, B; Krauth, M.-T.; Petzer, A.; Schmitt, C; Machherndl-Spandl, S.; Agis, H. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 80 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗